|
Canada-0-CARTAGE Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Pfizer, BioNTech halt US COVID vaccine study after recruitment . . . - MSN
Vaccine makers Pfizer PFE N and BioNTech 22UAy DE halted a large U S trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to
- Exclusive-Pfizer, BioNTech halt US COVID vaccine study after . . .
By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U S trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the
- Exclusive: Pfizer, BioNTech Halt US COVID Vaccine Study After . . .
By The Defender Staff Exclusive: Pfizer, BioNTech Halt US COVID Vaccine Study After Recruitment Struggles U S News World Report reported: Vaccine makers Pfizer and BioNTech halted a large U S trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data In a letter to trial investigators dated
- Pfizer, BioNTech halt US trial of COVID-19 vaccine over low enrollment
Pfizer and BioNTech have halted a major U S clinical trial of their updated COVID-19 vaccine in adults aged 50 to 64, citing insufficient participant enrollment to produce reliable data In a March 30 letter to investigators, seen by Reuters, Pfizer said it would stop monitoring participants for COVID-19 illness after April 3, effectively ending the study’s active surveillance phase
- Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow . . .
Pfizer and BioNTech have stopped enrollment in a large U S -based trial of their updated COVID-19 vaccine in response to slow enrollment The study was designed to recruit 25,000 to 30,000 healthy adults aged 50 to 64
- Pfizer, BioNTech halt US COVID vaccine study after recruitment . . .
Vaccine makers Pfizer and BioNTech halted a large U S trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the
- Pfizer, BioNTech to pause COVID vaccine study due to low enrollment
Pfizer and partner BioNTech said they will halt a government-ordered post-marketing study for their COVID-19 vaccine because of recruitment issues that, in turn, have impaired data collection The companies confirmed Wednesday, following a report from Reuters, that they are suspending the trial as a
- Pfizer-BioNTech Halt COVID-19 Vaccine Trial for Adults 50-64 Due to . . .
Pfizer and BioNTech have paused their large U S trial of an updated COVID-19 vaccine targeting adults aged 50 to 64 after failing to enroll the target 25,000 to 30,000 participants
- Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Pfizer and BioNTech have halted their U S COVID-19 vaccine trial for adults aged 50-64 due to low enrollment numbers The companies faced difficulties in meeting FDA requirements for large trials, leading to the suspension of recruitment and study monitoring Learn more about the implications of this decision on vaccine approvals
- Pfizer and BioNTech Hit the Brakes on a Key COVID Vaccine Trial
Key Points Pfizer and BioNTech have halted recruitment for a large U S trial of their updated COVID-19 vaccine for adults aged 50 to 64, citing insufficient enrollment The decision reflects broader challenges, including tighter FDA requirements for approval in this age group and declining public interest in boosters In a separate but significant development, Pfizer won a legal case in
|
|